New vaccine shows promise in targeting deadly brain tumors

A new vaccine has been developed to help the immune system target gliomas, a type of deadly brain tumor. This vaccine focuses on the IDH1 mutation, which is found in many gliomas, and has shown to be safe and effective in clinical trials. The research, led by Michael Platten, has been recognized with the “Breakthrough of the Year 2024” award. The vaccine enables the immune system to distinguish between normal proteins and those altered by cancer, allowing for precise targeting of tumor cells. Platten's work may extend beyond brain tumors, as the technology could potentially be applied to other cancers. The award will be presented at the Falling Walls Science Summit in Berlin on November 9, 2024.